The stock of pSivida Corp. (NASDAQ:PSDV) is a huge mover today! The stock decreased 5.35% or $0.17 during the last trading session, hitting $3.01. About 178,693 shares traded hands or 194.83% up from the average. pSivida Corp. (NASDAQ:PSDV) has risen 14.80% since February 26, 2016 and is uptrending. It has outperformed by 4.38% the S&P500.
The move comes after 9 months negative chart setup for the $100.66M company. It was reported on Oct, 1 by Barchart.com. We have $2.59 PT which if reached, will make NASDAQ:PSDV worth $14.09 million less.
According to Zacks Investment Research, “pSivida Corp., a specialty pharmaceutical company, combines existing drugs with its sustained release delivery technologies to develop transformational products primarily in ophthalmology. pSivida’s two proprietary technology systems are Durasert and Tethadur. Durasert delivers specific quantities of drugs at controlled rates for predetermined periods of time from weeks to months. pSivida has developed three of the four sustained delivery release devices for retinal diseases that have been approved in either the US or Europe, the most recent being ILUVIENÂ®, partnered with Alimera Sciences and approved in multiple EU countries. Independently, pSivida is developing an injectable, bioerodible product to treat glaucoma and ocular hypertension. Tethadur is a protein, peptide and antibody delivery system.”
Insitutional Activity: The institutional sentiment decreased to 0.73 in Q2 2016. Its down 0.08, from 0.81 in 2016Q1. The ratio worsened, as 6 funds sold all pSivida Corp. shares owned while 9 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 10.25 million shares or 3.57% less from 10.63 million shares in 2016Q1.
Geode Cap Mgmt Ltd Liability Co last reported 141,663 shares in the company. Morgan Stanley owns 274,233 shares or 0% of their US portfolio. Sabby Management Limited Liability last reported 0.04% of its portfolio in the stock. Blackrock Institutional Com Na has invested 0% of its portfolio in pSivida Corp. (NASDAQ:PSDV). Private Advisor Group Limited Company holds 22,700 shares or 0% of its portfolio. Finemark State Bank Tru accumulated 71,800 shares or 0.02% of the stock. Kcg holds 0% or 20,440 shares in its portfolio. Vanguard Group Inc Inc has 953,744 shares for 0% of their US portfolio. Renaissance Technology Ltd Co has 0% invested in the company for 586,900 shares. Gsa Capital Limited Liability Partnership reported 155,261 shares or 0.02% of all its holdings. Bard Assoc holds 105,609 shares or 0.16% of its portfolio. Deutsche Savings Bank Ag holds 199,003 shares or 0% of its portfolio. Credit Suisse Ag accumulated 0% or 52,440 shares. Natl Bank Of America De, a North Carolina-based fund reported 5,099 shares. Savings Bank Of New York Mellon Corp holds 0% or 57,637 shares in its portfolio.
More notable recent pSivida Corp. (NASDAQ:PSDV) news were published by: Globenewswire.com which released: “pSivida to Present at the Ladenburg Thalmann Annual Healthcare Conference” on September 22, 2016, also Globenewswire.com with their article: “Topline Results from First Phase 3 Trial of pSivida’s Medidurâ„¢ Presented at …” published on August 15, 2016, Finance.Yahoo.com published: “pSivida Corp. Announces Fourth Quarter and Fiscal Year 2016 Financial Results …” on September 01, 2016. More interesting news about pSivida Corp. (NASDAQ:PSDV) were released by: Quotes.Wsj.com and their article: “News pSivida Corp.PSDV” published on February 11, 2011 as well as Globenewswire.com‘s news article titled: “pSivida Corp. Provides Company Update and Reports Fourth Quarter and FY 2016 …” with publication date: September 12, 2016.
PSDV Company Profile
pSivida Corp., incorporated on March 20, 2008, develops drug delivery products primarily for the treatment of chronic eye diseases. The Firm operates through the biotechnology sector segment. The Firm has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. The Company’s product development program is focused primarily on utilizing its two core technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.